175 related articles for article (PubMed ID: 11179485)
1. Absence of p51 alteration in human ovarian cancer.
Shinozaki H; Okamoto A; Shimizu K; Saito M; Yokota J; Ochiai K
Int J Oncol; 2001 Mar; 18(3):549-52. PubMed ID: 11179485
[TBL] [Abstract][Full Text] [Related]
2. Mutational analysis of p51A/TAp63gamma, a p53 homolog, in non-small cell lung cancer and breast cancer.
Sunahara M; Shishikura T; Takahashi M; Todo S; Yamamoto N; Kimura H; Kato S; Ishioka C; Ikawa S; Ikawa Y; Nakagawara A
Oncogene; 1999 Jun; 18(25):3761-5. PubMed ID: 10391684
[TBL] [Abstract][Full Text] [Related]
3. Expression and mutational analysis of the DCC, DPC4, and MADR2/JV18-1 genes in neuroblastoma.
Kong XT; Choi SH; Inoue A; Xu F; Chen T; Takita J; Yokota J; Bessho F; Yanagisawa M; Hanada R; Yamamoto K; Hayashi Y
Cancer Res; 1997 Sep; 57(17):3772-8. PubMed ID: 9288786
[TBL] [Abstract][Full Text] [Related]
4. A commonly deleted region in ovarian cancer on chromosome 19p13.3, not including the OAZ1 gene.
Yanaihara N; Okamoto A; Matsufuji S
Int J Oncol; 2003 Sep; 23(3):567-75. PubMed ID: 12888889
[TBL] [Abstract][Full Text] [Related]
5. Analysis of the candidate 8p21 tumour suppressor, BNIP3L, in breast and ovarian cancer.
Lai J; Flanagan J; Phillips WA; Chenevix-Trench G; Arnold J
Br J Cancer; 2003 Jan; 88(2):270-6. PubMed ID: 12610513
[TBL] [Abstract][Full Text] [Related]
6. Suppression of ING1 expression in sporadic breast cancer.
Toyama T; Iwase H; Watson P; Muzik H; Saettler E; Magliocco A; DiFrancesco L; Forsyth P; Garkavtsev I; Kobayashi S; Riabowol K
Oncogene; 1999 Sep; 18(37):5187-93. PubMed ID: 10498868
[TBL] [Abstract][Full Text] [Related]
7. Mutational analysis of the p63/p73L/p51/p40/CUSP/KET gene in human cancer cell lines using intronic primers.
Hagiwara K; McMenamin MG; Miura K; Harris CC
Cancer Res; 1999 Sep; 59(17):4165-9. PubMed ID: 10485447
[TBL] [Abstract][Full Text] [Related]
8. Altered expression and loss of heterozygosity of the LOT1 gene in ovarian cancer.
Cvetkovic D; Pisarcik D; Lee C; Hamilton TC; Abdollahi A
Gynecol Oncol; 2004 Dec; 95(3):449-55. PubMed ID: 15581945
[TBL] [Abstract][Full Text] [Related]
9. Mutation and expression of the p51 gene in human lung cancer.
Tani M; Shimizu K; Kawahara C; Kohno T; Ishimoto O; Ikawa S; Yokota J
Neoplasia; 1999 Apr; 1(1):71-9. PubMed ID: 10935472
[TBL] [Abstract][Full Text] [Related]
10. Alterations in novel candidate tumor suppressor genes, ING1 and ING2 in human lung cancer.
Okano T; Gemma A; Hosoya Y; Hosomi Y; Nara M; Kokubo Y; Yoshimura A; Shibuya M; Nagashima M; Harris CC; Kudoh S
Oncol Rep; 2006 Mar; 15(3):545-9. PubMed ID: 16465410
[TBL] [Abstract][Full Text] [Related]
11. Reduced transcription of the RB2/p130 gene in human lung cancer.
Xue Jun H; Gemma A; Hosoya Y; Matsuda K; Nara M; Hosomi Y; Okano T; Kurimoto F; Seike M; Takenaka K; Yoshimura A; Toyota M; Kudoh S
Mol Carcinog; 2003 Nov; 38(3):124-9. PubMed ID: 14587097
[TBL] [Abstract][Full Text] [Related]
12. Allelic loss and reduced expression of the ING3, a candidate tumor suppressor gene at 7q31, in human head and neck cancers.
Gunduz M; Ouchida M; Fukushima K; Ito S; Jitsumori Y; Nakashima T; Nagai N; Nishizaki K; Shimizu K
Oncogene; 2002 Jun; 21(28):4462-70. PubMed ID: 12080476
[TBL] [Abstract][Full Text] [Related]
13. Effects of p51/p63 missense mutations on transcriptional activities of p53 downstream gene promoters.
Kato S; Shimada A; Osada M; Ikawa S; Obinata M; Nakagawara A; Kanamaru R; Ishioka C
Cancer Res; 1999 Dec; 59(23):5908-11. PubMed ID: 10606233
[TBL] [Abstract][Full Text] [Related]
14. A comparison of genomic structures and expression patterns of two closely related flanking genes in a critical lung cancer region at 3p21.3.
Timmer T; Terpstra P; van den Berg A; Veldhuis PM; Ter Elst A; Voutsinas G; Hulsbeek MM; Draaijers TG; Looman MW; Kok K; Naylor SL; Buys CH
Eur J Hum Genet; 1999; 7(4):478-86. PubMed ID: 10352938
[TBL] [Abstract][Full Text] [Related]
15. Absence of p51 mutation in human hepatocellular carcinoma.
Hamada K; Koyama T; Shimizu K; Ikawa S; Kawate S; Yokota J; Ohwada S; Morishita Y
Cancer Lett; 2000 Feb; 148(2):161-4. PubMed ID: 10695992
[TBL] [Abstract][Full Text] [Related]
16. Frequent down-regulation and lack of mutation of the KAI1 metastasis suppressor gene in epithelial ovarian carcinoma.
Liu FS; Dong JT; Chen JT; Hsieh YT; Ho ES; Hung MJ
Gynecol Oncol; 2000 Jul; 78(1):10-5. PubMed ID: 10873402
[TBL] [Abstract][Full Text] [Related]
17. No mutations of the Bub1 gene in human gastric and oral cancer cell lines.
Nakagawa H; Yokozaki H; Oue N; Sugiyama M; Ishikawa T; Tahara E; Yasui W
Oncol Rep; 2002; 9(6):1229-32. PubMed ID: 12375025
[TBL] [Abstract][Full Text] [Related]
18. Decreased expression of the Id3 gene at 1p36.1 in ovarian adenocarcinomas.
Arnold JM; Mok SC; Purdie D; Chenevix-Trench G
Br J Cancer; 2001 Feb; 84(3):352-9. PubMed ID: 11161400
[TBL] [Abstract][Full Text] [Related]
19. [Alterations in DPC4 gene in pancreatic cancers].
Gu L; Chen J; Cui Q
Zhonghua Zhong Liu Za Zhi; 2001 Jul; 23(4):293-5. PubMed ID: 11783110
[TBL] [Abstract][Full Text] [Related]
20. Decreased expression of the candidate tumor suppressor gene ING1 is associated with poor prognosis in advanced neuroblastomas.
Takahashi M; Ozaki T; Todo S; Nakagawara A
Oncol Rep; 2004 Oct; 12(4):811-6. PubMed ID: 15375504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
